Reducing risk and uncertainty in the drug development enterprise was an underlying theme in the activities of the National Academies’ Forum on Drug Discovery, Development, and Translation (the Forum) in 2012. In addition to leveraging opportunities to work with federal agencies, the Forum contributed to broad conversations on biomedical research and policy, including examining the benefits and barriers to sharing clinical research data to facilitate scientific and public health advances. The Forum membership focused on ways to address challenges in the U.S. clinical trials enterprise, facilitated a public dialogue on opportunities to accelerate the use of large simple trials, and fostered collaborative action to advance the development of a national certification system for clinical trial sites. Additionally, the Forum examined problems in the global drug supply chain for medicines to treat neglected diseases, such as multidrug-resistant tuberculosis.
For more information, please see https://www.nationalacademies.org/our-work/forum-on-drug-discovery-development-and-translation.
Table of Contents
|Message from the Co-Chairs||2-3|
|Reflecting Back: Forum Activities in 2012||4-9|
|Looking Forward: Forum Activities in 2013||10-11|
|Forum Members and Sponsorship||18-20|
The National Academies Press and the Transportation Research Board have partnered with Copyright Clearance Center to offer a variety of options for reusing our content. You may request permission to:
For most Academic and Educational uses no royalties will be charged although you are required to obtain a license and comply with the license terms and conditions.
For information on how to request permission to translate our work and for any other rights related query please click here.
For questions about using the Copyright.com service, please contact:
Copyright Clearance Center
22 Rosewood Drive
Danvers, MA 01923
Tel (toll free): 855/239-3415 (select option 1)
Loading stats for Forum on Drug Discovery, Development, and Translation: 2012 Annual Report...